Background. High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes. Methods. Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor a and immunocytochemistry with ACE and ACE2 antibodies. Results. Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and
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I N T R O D U C T I O N
Systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS) are highly associated with chronic kidney disease (CKD) as manifested in about one-third of the patients maintained on regular haemodialysis (HD). Elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumour necrosis factor (TNF) [1, 2] are well-established pro-inflammatory predictors for increased risk of atherosclerotic complications and adverse cardiovascular events related to high mortality rates [3] [4] [5] .
Recent data suggest that the RAS is not only an important element in the control of blood pressure, but also a modulating factor in the progression of atherosclerosis. Continuous activation and recruitment of circulating leucocytes to the sites of inflammation triggered by an overactivated RAS may promote the development of atherosclerotic plaques [6, 7] . In addition to these findings, circulating leucocytes, especially monocytes, possess their own functional RAS components that modulate local immune response and behaviour of the cells. We demonstrated that augmented levels of monocytic angiotensin-converting enzymes (ACE and ACE2) in HD patients are associated with increased mortality and cardiovascular morbidity and may also contribute to the initial steps of atherosclerosis [8] [9] [10] . Our recent investigations revealed that uraemic conditions promote overactivation of monocytic ACE and inhibition of ACE2, thus contributing to enhanced endothelial adhesion and transmigration of the monocytes [11, 12] .
Conventional HD with high-flux (HF) membranes insufficiently eliminates pro-inflammatory mediators [13, 14] ; their accumulation may lead to modulation of components of the local, leucocytic RAS. High cut-off (HCO) membranes, especially those with a nominal cut-off point of 45 kDa (HCO1100, Gambro), have been successfully employed for the treatment of light-chain nephropathy in patients with multiple myeloma [15] [16] [17] and septic shock [18] . Recently, the employment of HCO and newly developed medium cut-off (MCO) membranes [19] for treatment of chronic HD patients with elevated CRP led to the reduced expression of multiple pro-inflammatory genes in leucocytes [20] [21] [22] [23] .
In this study we investigated the possible impact of high-permeability HD on leucocytic ACE/ACE2 transcripts and the receptors for angiotensin II (AngII; AT1R, AT2R) and Ang1-7 (MAS1 receptor; MASR) within two randomized, double-blind, crossover pilot trials. Furthermore, we tested whether employment of high-permeability membranes is able to modulate the expression of monocytic ACE/ACE2 as well as TNF-a and IL-6 messenger RNA (mRNA) in THP-1 cells.
M A T E R I A L S A N D M E T H O D S
Patients and study treatments HCO trial: The clinical trials were conducted as described previously (ClinicalTrials.gov, NCT01582893) [22] . Briefly, 43 chronic dialysis patients were included and dialysed with HCO and regular HF membranes in a randomized order following a two-period crossover design. During the trial, every patient was dialysed with each type of membrane (single use) for 3 weeks, with run-in and washout phases of 2 weeks in between.
MCO trial: The clinical trial was conducted as described previously (ClinicalTrials.gov, NCT020843) [23] . Briefly, 48 chronic dialysis patients were included and dialysed with an MCO prototype and regular HF membranes in a randomized order following a two-period crossover design. During the trial, every patient was dialysed with each type of membrane (single use) for 4 weeks, with run-in and washout phases of 4 weeks in between.
Dialysis in vitro
Heparin anticoagulated blood from three healthy volunteers (500 mL each) was incubated for 6 h with 100 EU/mL endotoxin at 37 C. Subsequently, isolated plasma was pooled and subjected to 90 min in vitro dialysis with HF, HCO and MCO membranes according to Supplementary data, Figure S1 . The bicarbonate dialysis fluid was prepared according to the manufacturer's instructions from concentrates D227 and D200 (MTN Neubrandenburg, Neubrandenburg, Germany) and was recirculated. Plasma and dialysate fluids were employed for assays in vitro.
THP-1 incubation with serum and dialysate
Serum samples were drawn prior to the first dialysis session after the weekend, centrifuged at 2000 g for 15 min and then stored at À80 C. Serum was also obtained from patients at the end of each HF-, HCO-and MCO-membrane treatment and frozen and stored at À80 C until analysis. THP-1 monocytes were incubated at 1 Â 10 6 /mL for 4 h. All treatments were performed in hydrophobic 6-well plates (Greiner Bio-One, Frickenhausen, Germany) in a standard humidified incubator (37 C, 5% CO 2 ) in RPMI (Sigma, Taufkirchen, Germany) medium supplemented with 1.125 g/L sodium bicarbonate and 100 mg/mL penicillin/streptomycin (Biochrom/Millipore, Darmstadt, Germany). Sera from the patient studies or plasma from dialysis in vitro were used at a final concentration of 10% in RPMI medium.
For the treatments with the dialysates obtained from in vitro dialyses, the cells were incubated with RPMI medium containing 10% HF, HCO or MCO dialysates for 4 h.
Total RNA for gene expression analyses was extracted from all treatments.
Quantitative polymerase chain reaction (qPCR) analyses
Total RNA was isolated using the ZR RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions.
Blood samples for mRNA analysis were drawn into PAXgene Blood RNA (Qiagen/PreAnalytiX, Hombrechtikon, Switzerland) or Tempus Blood RNA Tubes (Thermo Fisher Scientific, Waltham, MA, USA) prefilled with RNase inhibitor and frozen at À80
C or À20 C, respectively. Total RNA was isolated with the PAXgene Blood RNA Kit (Qiagen/PreAnalytiX) or Tempus Spin RNA Isolation Kit (Thermo Fisher Scientific).
A total of 500 ng of total RNA was reversely transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA). The samples were stored at À20 C. All qPCRs were performed in a StepOnePlus Real-Time PCR System (Life Technologies) in MicroAmp 96-well plates. Samples were amplified as double replicates by employment of the following TaqMan assays (Life Technologies): ACE, ACE2, MASR (Hs00267157_s1), TNF-a (Hs01113624_g1), IL-6 (Hs00985639_m1), ACTB (beta-actin; Hs99999903_m1) and RPL37A (ribosomal protein L37A; Hs99999903_m1), and primers specific for AT1R (angiotensin II type 1 receptor; S- 
samples, internal calibrator cDNA (positive control) and negative controls. For evaluation, each patient sample with amplified target gene was normalized to ACTB and RPL37A and divided by the internal calibrator to obtain the fold change value (RQ). For the whole study, internal calibrator, negative controls and normalizing markers were employed. Data evaluation was performed with DataAssist Software (Life Technologies).
Immunocytochemistry
In all, 1 Â 10 5 THP-1 cells were seeded on chamber slides (Thermo Fisher Scientific) and left to grow in normal medium for 24 h. Thereafter, the cells were gently washed with phosphate-buffered saline (PBS) and incubated with foetal calf serum-free RPMI medium containing 10% pooled HF or HCO or MCO study sera for 4 h. Thereafter, the cells were fixed with 10% formalin solution in PBS for 10 min. After washing twice with PBS, the cells were incubated for 1 h at room temperature with normal goat serum (diluted 1:500 in PBS), followed by incubation overnight at 4 C with polyclonal rabbit antibodies against ACE or ACE2 (ab85955 or ab15348, respectively, both diluted 1:1000 with PBS; both from Abcam, Cambridge, MA, USA). Negative control sections were exposed to the secondary antibody only and processed as described below. After 3 Â 10 min washing in PBS, cells were incubated for 1 h with a 1:1000 dilution of biotinylated anti-rabbit secondary antibody followed by incubation with an avidin-biotin-peroxidase complex. After 3 Â 10 min washing in PBS, specific immunostaining was visualized with diaminobenzidine chromogenic solution (1:50). Finally, cells were lightly counterstained with Mayer's haematoxylin. Microscopic investigations were performed with a light/fluorescence microscope (Biozero BZ-9000, Keyence, Osaka, Japan).
Statistics
Each experiment was repeated at least three times. Data are presented as medians with interquartile range (IRQ). Distribution of the quantitative variables was tested using D'Agostino-Pearson omnibus, Shapiro-Wilk or KolmogorowSmirnow normality tests. A linear regression model was applied to test whether expression parameters are dependent on the starting membrane. If indicated, log transformations were applied. Depending on data distribution two-sided t-tests for paired samples or nonparametric Wilcoxon signed-rank tests were used. P-values < 0.05 were considered to be statistically significant. GraphPad Prism (GraphPad Software, La Jolla, CA, USA) and SPSS software were used for statistical analyses.
R E S U L T S
Employment of HCO and MCO dialysis in vitro regulates the transcripts of TNF-a, IL-6 and ACE2 in human THP-1 monocytes Initial testing of the high-permeability membranes was performed by employment of in vitro dialysis with HF, HCO or MCO membranes. THP-1 monocytes were treated with in vitro dialyzed plasma and fluids obtained from healthy, endotoxinspiked whole blood. As demonstrated in Figure 1A and B, the cells incubated with HCO or MCO plasma reacted with noticeably decreased levels of TNF-a and IL-6 mRNAs as compared with the incubation with HF plasma. Furthermore, the same treatments led to downregulation of ACE transcripts and significant upregulation of ACE2 expression ( Figure 1C and D) . Visualization of these data as the proportion between both ACEs demonstrated that the expression ratio ACE2:ACE was significantly elevated in the HCO and MCO treatments as compared with HF ( Figure 1E) .
Employment of the dialysate fluids to the cells revealed contrary effects to those observed with plasma incubation. As demonstrated in Figure 2A and B, THP-1 monocytes reacted with upregulated levels of TNF-a and IL-6 transcripts under HCO or MCO dialysates as compared with HF. With regard to monocytic ACEs, HCO or MCO dialysate treatments led to an ACE increase, while ACE2 transcript expression was downregulated ( Figure 2C and D) . Opposite to plasma incubations, the expression ratio of ACE2:ACE was significantly Figure 2E ).
Expression of leucocytic ACE2 transcripts is significantly elevated in patients under HCO and MCO HD
In order to investigate the transcript expression pattern of ACE and ACE2 in the cells circulating in patients maintained on different membranes, we subjected the leucocytes obtained from HF, HCO and MCO treatments to qPCR with specific ACE, ACE2 and MASR probes and AT1R and AT2R primers. As demonstrated in Figure 3A and C, ACE expression in the HCO and MCO groups revealed the decreasing tendency as compared with HF treatments. In contrast, the levels of ACE2 mRNA were significantly increased in the HCO and MCO groups ( Figure 3B and D) , also regarding the crossover periods ( Figure 4A and B) .
Investigations of leucocytic balance between both ACEs demonstrated that the expression ratio of ACE2:ACE was significantly elevated in the HCO and MCO groups as compared with HF treatment (Figure 3E and F) .
Expression of leucocytic mRNAs encoding AngII receptors and MASR is not affected under HCO and MCO HD
The expression of leucocytic transcripts for ACE and ACE2 differ noticeably between patients maintained on high-permeability membranes and HF. However, further investigations on leucocytic mRNAs encoding AngII receptors (AT1R and AT2R) and receptor for Ang1-7 (MASR) showed no significant expression difference in any of the tested membranes ( Figure  5A-F) .
ACE pattern in THP-1 cells reflects the expression observed in HCO and MCO HD patients
Plasma and dialysis fluids obtained from in vitro dialysis with endotoxin-spiked blood revealed that HCO and MCO membranes are able to not only decrease the inflammation profile in THP-1 monocytes, but also to regulate the transcript expression of ACEs, especially ACE2. These effects were further verified on THP-1 monocytes treated with study sera. As demonstrated in Figure 6 , THP-1 cells revealed the same expression pattern as those observed on patients' leucocytes and dialysis in vitro. Treatment of the monocytes with HCO and MCO sera led to significantly elevated levels of ACE2 mRNA as compared with HF. The same expression pattern could be demonstrated on protein level, immunocytochemically, as the THP-1 monocytes revealed noticeably stronger ACE2 staining under treatment with HCO and MCO sera as compared with HF. The decreasing tendency of ACE expression under HCO and MCO sera was noticed, however, the differences were not significant.
D I S C U S S I O N
This study demonstrates clearly that treatment of chronic dialysis patients with high-permeability membranes rather than conventional HF membranes modulate the local RAS response by altering the relation between ACE2 and ACE transcripts in circulating leucocytes.
Our previous investigations revealed that ACE2 on leucocytes obtained from healthy individuals is noticeably stronger compared with HD patients. As the uraemic milieu induces a specific dysregulation of ACE/ACE2 expression which is responsible for the formation of a pro-inflammatory and adhesive leucocyte phenotype [12] , employment of high-permeability membranes may reverse this phenotype towards a more favourable one. Zickler et al. [24] demonstrated that human coronary vascular smooth muscle cells (VSMCs) in the presence of HCO serum showed decreased calcification as compared with HF. As the serum obtained from patients maintained on HCO membranes contains less vascular cell adhesion molecule 1 (VCAM-1) and VCAM-1 itself is able to increase calcification of VSMC in vitro, the beneficial effects of HCO dialysis should be taken into consideration [24] . In our previous studies, the ACE-mediated pro-atherogenic phenotype of human Many studies have reported a protective role for ACE2 and the involvement of the ACE2/Ang1-7/Mas receptor axis in the modulation of oxidative stress, renal fibrosis and inflammation [25] [26] [27] [28] [29] [30] . Thus the clear advantages of ACE2 activation for the treatment of kidney and cardiovascular disorders are obvious. It has been demonstrated that administration of xanthenone and diminazene aceturate, two ACE2 activators, to hypertensive rats led to decreased blood pressure, reversed myocardial and perivascular fibrosis and improved myocardial function [31] [32] [33] [34] . Also, infusion of recombinant ACE2 slowed the progression of diabetic nephropathy [22, 35] and attenuated AngII-induced tubulointerstitial fibrosis [36] . Recently, Bossi et al. [37] reported that intraperitoneal injection of Ang1-7 prevented in vivo diabetes-induced leucocyte adhesion and extravasation in Wistar rats. We demonstrated previously that induction of ACE2 overexpression in human THP-1 monocytes contributes to diminished endothelial adhesion and transmigration of these cells [12] .
The classical RAS inhibitors may also indirectly increase the levels of Ang1-7 and ACE2. In a model of hypertensive nephropathy, administration of olmesartan, an AT1R antagonist, led to increased levels of Ang1-7, resulting in cardio-and renoprotective effects [38] . In an other animal model, administration of losartan or lisinopril [AT1R antagonist and ACE inhibitor (ACEi), respectively] to Lewis rats elevated plasma and urinary concentrations of Ang1-7 and renal activity of ACE2 [39] . It is worth noting that in this study the RAS-modifying medication had no effect on ACE, MASR and AT1 receptors.
Almost 70% of the patients investigated in our study received RAS-modifying medication [HCO trial: ACEi 32.5%, angiotensin II receptor blocker (ARB) 37.5%; MCO trial: ACEi 47.8%, ARB 32.6%], which had no influence on any of the In addition, investigations of leucocytic ACE, AngII and MAS receptors revealed no significant difference between patients treated with HF and high-permeability HD. In contrast, the level of leucocytic ACE2 was significantly upregulated regardless of RAS-modifying medication. We postulate that within CKD patients, as previously reported by Chon et al. [40] , inappropriately high levels of leucocytic ACE or AT1R may result due to the dominating uraemic environment, which is the stronger RAS modulator. Since RAS-modifying treatments [12] and the permeability of membranes are not the reason for direct ACE2 regulation, leucocytic increase in ACE2 expression cannot be explained by HCOor MCO-mediated elimination. Instead, a decrease of other inflammation mediators related to secondary ACE2 upregulation is a possible explanation. We showed previously and also in this study that treatment of human THP-1 monocytes with sera obtained from HCO or MCO dialysis led to a diminished expression profile of many transcripts related to inflammation, including pro-inflammatory TNF-a and IL-6 [41] .
It has been demonstrated that serum albumin concentrations are significantly lower with both HCO and MCO membranes as compared with HF. Thus the elimination of albumin-bound toxins or even albumin lost itself might induce the expression of ACE2 on leucocytes. This possible explanation could be supported by the fact that treatment of proximal tubule epithelial cells (HK-2) with bovine serum [42] . Additionally, M arquez et al. [43] demonstrated that albumin inhibits the insulinmediated ACE2 increase in cultured podocytes.
Currently there are no data demonstrating a direct correlation between removal of free or protein-bound uraemic toxins and the upregulation of leucocytic ACE2. However, several reports have demonstrated that uraemic toxins may induce other components of the RAS, such as renin, angiotensinogen and AngII receptor [44, 45] . Studies by Pletinck et al. [46] and Vanholder et al. and Pletinck et al. [47] revealed that proinflammatory effects triggered by protein-bound uraemic toxins contribute to vascular damage and renal disease progression by stimulating crosstalk between leucocytes and the vessel wall.
In this view, we speculate that greater elimination of proteinbound uraemic toxins by high-permeability dialysis may be a possible explanation for increased expression of leucocytic ACE2.
Thus we cannot exclude the possibility that elimination of protein-bound uraemic toxins due to greater albumin leakage, as observed in patients maintained on high-permeability HD, may be related with increased beneficial ACE2/ACE balance in circulating leucocytes.
Finally, the modulation of ACE2 expression could be the subject of post-translational regulation by circulating microRNAs (miRNAs). It has been demonstrated that miR-421 is able to bind and downregulate ACE2 mRNA, thus elimination of this miRNA from serum might elevate ACE2 levels [48] . However, current data reveal that elimination of miRNAs by HD per se is rather controversial, demonstrating that some miRNAs are removed by HD and others not, even with filters with the molecular weight cut-off (MWCO) up to 40 kDa [49, 50] . Both HCO and MCO membranes allow for high permeability of molecules up to a molecular weight of 45 kDa; whether ACE2 can be regulateds in an miRNA-mediated manner requires further investigation.
In summary, we demonstrated that high-permeability HD is able to modulate the transcript expression of local RAS components. Increased levels of leucocytic ACE2 over ACE induced by HCO and MCO HD treatment may contribute to the antiinflammatory and anti-atherogenic effects as reported previously. Future improvements of the membrane nominal cut-off 
Limitations
Even though this study was performed on samples originating from HD patients maintained on different dialysis membranes, we must point out several limitations. By design, assessment of the leucocytic parameters was possible on the transcript level only. Although the high-permeability HD upregulated ACE2 mRNA in patients' leucocytes to a greater extent than HF hD, the protein regulation could be verified in vitro only. Our ex vivo data come from the transcript level and have to be interpreted as such. We believe that both mRNA and protein levels in circulating leucocytes correspond with each other. The lack of functional leucocytic data, which is a noticeable limitation of this study, should be addressed in future clinical trials with high-permeability HD.
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